How to distinguish between the activity of HDAC1-3 and HDAC6 with Western blot

Methods in Molecular Biology

Volumn 1510, Issue , 2017, Pages 355-364

  Beyer, Mandy ^a   Kiweler, Nicole ^a   Mahboobi, Siavosh ^b   Krämer, Oliver H ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Acetylation; HDAC6; HDACi; HDACs; Histone; Tubulin

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; BENZAMIDE DERIVATIVE; ENTINOSTAT; HDAC1 PROTEIN, HUMAN; HDAC2 PROTEIN, HUMAN; HDAC6 PROTEIN, HUMAN; HISTONE; HISTONE DEACETYLASE; HYDROXAMIC ACID; INDOLE DERIVATIVE; PANOBINOSTAT; PYRIDINE DERIVATIVE; VALPROIC ACID;

CELL LYSATE; DEACETYLATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME MECHANISM; HISTONE ACETYLATION; PROTEIN ACETYLATION; WESTERN BLOTTING; ACETYLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; EPITHELIUM CELL; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; MONOCYTE; MOUSE; PROCEDURES; PROTEIN PROCESSING; TUMOR CELL LINE;

ACETYLATION; ANIMALS; BENZAMIDES; BLOTTING, WESTERN; CELL LINE, TUMOR; EPIGENESIS, GENETIC; EPITHELIAL CELLS; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; INDOLES; MICE; MONOCYTES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRIDINES; VALPROIC ACID;

EID: 84992427926     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-6527-4_26     Document Type: Chapter

References (20)

1. Spange S, Wagner T, Heinzel T, Krämer OH (2009) Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 41:185–198
2. Villagra A, Sotomayor EM, Seto E (2009) Histone deacetylases and the immunological network: implications in cancer and inflammation. Oncogene 29:157–173
3. Buchwald M, Krämer OH, Heinzel T (2009) HDACi—targets beyond chromatin. Cancer Lett 280:160–167
4. Krämer OH (2009) HDAC2: a critical factor in health and disease. Trends Pharmacol Sci 30:647–655
5. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN (2004) Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59:177–189
6. Wilson AJ, Byun DS, Popova N, Murray LB, L’Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH, Mariadason JM (2006) Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281: 13548–13558
7. Lee SH, Yoo C, Im S, Jung JH, Choi HJ, Yoo J (2014) Expression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significance. Int J Med Sci 11:994–1000
8. Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Hara Y, Kobayashi S, Iwase H (2005) Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res Treat 94:11–16
9. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Göttlicher M (2004) Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5: 455–463
10. Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y, Mita K, Hamaguchi M, Hayashi S, Iwase H (2004) HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 10:6962–6968
11. Falkenberg KJ, Johnstone RW (2014) Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 13:673–691
12. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769–784
13. Parmigiani RB, Xu WS, Venta-Perez G, Erdjument-Bromage H, Yaneva M, Tempst P, Marks PA (2008) HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci U S A 105: 9633–9638
14. Krämer OH, Mahboobi S, Sellmer A (2014) Drugging the HDAC6-HSP90 interplay in malignant cells. Trends Pharmacol Sci 35:501–509
15. Bradner JE, Mak R, Tanguturi SK, Mazitschek R, Haggarty SJ, Ross K, Chang CY, Bosco J, West N, Morse E, Lin K, Shen JP, Kwiatkowski NP, Gheldof N, Dekker J, DeAngelo DJ, Carr SA, Schreiber SL, Golub TR, Ebert BL (2010) Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A 107:12617–12622
16. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969–6978
17. Bhalla KN (2005) Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23:3971–3993
18. Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF, Johanson K, Liu R, Lago A, Hofmann G, Macarron R, de los Frailes M, Perez P, Krawiec J, Winkler J, Jaye M (2003) Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 307:720–728
19. Maiso P, Carvajal-Vergara X, Ocio EM, Lopez- Perez R, Mateo G, Gutierrez N, Atadja P, Pandiella A, San Miguel JF (2006) The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 66:5781–5789
20. Brandl A, Heinzel T, Krämer OH (2009) Histone deacetylases: salesmen and customers in the post-translational modification market. Biol Cell 101:193–205